Isatuximab
Based on 1 publication(s) in Google Scholar
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.5%
- CAS No.: 1461640-62-9
- 분자량:145.2 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Isatuximab
More
Biological Activity
Human IgG1 kappa
Human
CD38
An in-vitro study shows that the combination of Isatuximab with Pomalidomide results in greater direct toxicity and lysis of CD38 multiple myeloma cells by effector cells compared with Isatuximab alone[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized CD38 Protein, Human can bind Isatuximab. The EC50 for this effect is 6.163 ng/mL. -
Flow Cytometry analysis of Raji cells labelling CD38 (red) with Isatuximab (anti-CD38) (HY-P9976). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS No. 1461640-62-9
-
Appearance Liquid
-
분자량 145.2 kDa
-
Color Colorless to light yellow
-
SMILES
[Isatuximab]
-
Synonyms
ch38SB19; hu38SB19; SAR-650984
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
NAD+ exhaustion by CD38 upregulation contributes to blood pressure elevation and vascular damage in hypertension. [Abstract]2023 Sep 18;8(1):353. PMID: 37718359
순도&문서
-
Data Sheet (259 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Dhillon S. Isatuximab: First Approval [published correction appears in Drugs. 2020 May 23;:]. Drugs. 2020;80(9):905-912. [Content Brief]
[2]. Attal M, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study [published correction appears in Lancet. 2019 Dec 7;394(10214):2072]. Lancet. 2019;394(10214):2096-2107. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)